The stock will trade on Phase 2a and Phase 1 topline data catalysts this summer, not on Q1 financials. Watch for sweat chloride data from PreciSION CF — a clinically meaningful reduction would validate SION-719's mechanism and likely drive a re-rating. The 88% analyst buy rating and $2.1B market cap already price in some optimism; a data miss would be severely punished given the binary nature of the readout.
Price Chart
Executive Summary
Sionna reported Q1 2026 GAAP EPS of -$0.60, a 3.2% beat vs consensus of -$0.62, but net loss widened to $26.8M from $16.5M a year ago on higher R&D and G&A spending. The key catalyst is the on-track summer 2026 topline data from the Phase 2a PreciSION CF trial and Phase 1 dual-combination trial, which will determine whether SION-719 can expand CF treatment options. Cash of $289.9M funds operations into 2028, removing near-term dilution risk.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP EPS -$0.60 vs consensus -$0.62 (3.2% beat)
- Net loss widened to $26.8M from $16.5M YoY on higher R&D ($19.0M vs $13.7M) and G&A ($10.6M vs $6.0M)
- Phase 2a PreciSION CF trial of SION-719 enrollment completed; topline data expected summer 2026
- Phase 1 dual-combination trial of SION-451 with SION-2222 and SION-109 on track for summer 2026 topline data
- Cash, cash equivalents and marketable securities $289.9M; expected to fund operations into 2028
- No revenue reported (pre-commercial biotech)
Financial Impact
Net loss of $26.8M in Q1 2026 vs $16.5M in Q1 2025; cash burn rate ~$10M/month
Risk Factors
- Phase 2a topline data could fail to show clinically meaningful sweat chloride reduction, undermining the NBD1 stabilizer thesis
- Cash burn rate increased 62% YoY; if data disappoints, financing risk emerges despite current runway into 2028
- Insider selling of $31.7M in last 30 days may signal lack of confidence ahead of data readout
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292667 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $4.50 $7.30 | ▼ −62.22% | ▼ −63.14% | $5.04 (−12.00%) |
Aug 6, 2026 8w ago | 8-K | $49.61 $6.75 | ▼ −86.39% | ▼ −86.99% | $5.04 (−89.84%) |
Jul 9, 2026 12w ago | Insider Cluster | $45.29 $51.04 | ▲ +12.70% | ▲ +10.27% | $5.04 (−88.87%) |
Jul 9, 2026 12w ago | Insider Cluster | $45.29 $51.04 | ▼ −12.70% | ▼ −10.27% | $5.04 (+88.87%) |
Jul 7, 2026 12w ago | Insider Cluster | $44.00 $47.34 | ▼ −7.59% | ▼ −4.32% | $5.04 (+88.55%) |
Jul 2, 2026 13w ago | Insider Cluster | $43.99 $46.78 | ▲ +6.34% | ▲ +6.76% | $5.04 (−88.54%) |
Jun 11, 2026 16w ago | Institutional Cluster | $36.05 $44.94 | ▲ +24.66% | ▲ +22.77% | $5.04 (−86.02%) |
May 30, 2026 17w ago | Insider Cluster | $40.90 $43.99 | ▲ +7.55% | ▲ +8.85% | $5.04 (−87.68%) |
May 29, 2026 17w ago | 144 | $40.90 $43.99 | ▼ −7.55% | ▼ −8.85% | $5.04 (+87.68%) |
May 12, 2026 20w ago | 8-K | $40.94 $34.03 | ▼ −16.88% | ▼ −15.15% | $5.04 (−87.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access